Search
for
Did you mean SALT Score?
Sort by
Research 30 of 1000+
- Quantifying Alopecia Areata via Texture Analysis to Automate the SALT Score Computation
- Evaluation of SALT score severity in correlation with trichoscopic findings in alopecia areata: a study of 303 patients
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- Complete responses and SALT zero scores in alopecia areata: not the same
- Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial
- 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
- SALT Score Cards: Facilitating SALT Score Calculation in Alopecia Areata
- Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
- rwSALT: a regrowth-weighted SALT score providing direct pixel-level measurement rather than visual estimation
- rwSALT: a regrowth-weighted SALT score providing direct pixel-level measurement rather than visual estimation
- 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
- Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
- Using qualitative methods to establish the clinically meaningful threshold for treatment success for the Severity of Alopecia Tool (SALT) score
- 125: Individual Severity of Alopecia Tool (SALT) score trajectories of roll-over adolescent patients with alopecia areata (AA) treated with ritlecitinib in the ongoing long-term, open-label, phase 3 ALLEGRO-LT study
- Quantitative evaluation of carcinosin as an individualized remedy in pediatric alopecia areata using salt score and ludwig hair loss scales: A case report
- Using artificial intelligence to compute Severity of Alopecia Tool scores
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- 701 Rethinking alopecia scores: Correlating measures of hair loss with established photographic scoring systems
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- Tofacitinib for the treatment of alopecia areata and variants in adolescents
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
- Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata